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Microenvironment inflammatory infiltrate drives growth
speed and outcome of hepatocellular carcinoma: a
prospective clinical study
Rosina Critelli1,2,9, Fabiola Milosa1,2,9, Francesca Faillaci1,2, Rosario Condello1, Elena Turola3, Luca Marzi1, Barbara Lei1,2,
Francesco Dituri3, Silvia Andreani1,2, Pamela Sighinolfi4, Paola Manni4, Antonino Maiorana4, Cristian Caporali5, Fabrizio di Benedetto6,
Mariagrazia Del Buono1,2, Nicola De Maria1, Filippo Schepis1, Maria-Luz Martinez-Chantar2,7,8, Gianluigi Giannelli3 and Erica Villa*,1,2
In HCC, tumor microenvironment, heavily influenced by the underlying chronic liver disease, etiology and stage of the tissue
damage, affects tumor progression and determines the high heterogeneity of the tumor. Aim of this study was to identify the
circulating and tissue components of the microenvironment immune-mediated response affecting the aggressiveness and the
ensuing clinical outcome. We analyzed the baseline paired HCC and the surrounding tissue biopsies from a prospective cohort of
132 patients at the first diagnosis of HCC for immunolocalization of PD-1/PD-L1, FoxP3, E-cadherin, CLEC2 and for a panel of 82
microRNA associated with regulation of angiogenesis, cell proliferation, cell signaling, immune control and autophagy. Original
microarray data were also explored. Serum samples were analyzed for a panel of 19 cytokines. Data were associated with
biochemical data, histopathology and survival. Patients with a more aggressive disease and shorter survival, who we named fast-
growing accordingly to the tumor doubling time, at presentation had significantly higher AFP levels, TGF-β1 and Cyphra 21-1
levels. Transcriptomic analysis evidenced a significant downregulation of CLEC2 and upregulation of several metalloproteinases.
A marked local upregulation of both PD-1 and PD-L1, a concomitant FoxP3-positive lymphocytic infiltrate, a loss of E-cadherin,
gain of epithelial–mesenchymal transition (EMT) phenotype and extreme poor differentiation at histology were also present.
Upregulated microRNA in fast-growing HCCs are associated with TGF-β signaling, angiogenesis and inflammation. Our data show
that fast HCCs are characterized not only by redundant neo-angiogenesis but also by unique features of distinctively
immunosuppressed microenvironment, prominent EMT, and clear-cut activation of TGFβ1 signaling in a general background of
long-standing and permanent inflammatory state.
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The molecular basis regulating tumor progression of hepato-
cellular carcinoma (HCC) are still unclear, although a growing
evidence of data suggests that the tumor microenvironment is
a key player.1–3 The different biochemical composition of such
microenvironment derives from the underlying chronic liver
disease, from the different etiologies and from the stage of the
liver damage, all of this contributing to explain the high
heterogeneity of HCC.4 The different composition and
distribution of the extra-cellular matrix proteins, secreted by
the activated hepatic stellate cells as consequence of the
inflammatory stimuli, and how the HCC cells engagewith them
to negotiate their advancing across the tissue boundaries can
characterize more aggressive type of cancer.5 The epithelial-
to-mesenchymal transition is a process orchestrated by the
transforming growth factor (TGF)-β1, stored in the ECM-
enriched tissue in which HCC cells are embedded.6 The
proteolytic remodeling of the tissue microenvironment finely
modulates the dynamic cross-talk, explaining the relevance of
the peritumoral tissue also as potential therapeutic target. The
immunological components of the tissue microenvironment
are currently considered fundamental to regulate tumoral
progression, so that the programmed cell death protein 1
(PD-1)/programmed death-ligand 1 (PD-L1) immune check
point is targeted by specific inhibitors in a number of different
malignancies including melanoma, non-small cell lung cancer,
renal cell carcinoma, head and neck cancer and bladder
cancer. Most recently, clinical trials were started also in
patients with advanced HCC.
All these data strongly suggest that understanding the
cross-talk between the advancing tumor and the host tissue
is of paramount relevance towards a precision medicine in
patients with HCC. Indeed, all the most used prognostic
scores, including the Barcelona Cancer Liver Center, fail to
predict the clinical outcome of HCC patients in the everyday
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practice.7 Different molecular classification of HCC, derived
from high-throughput studies, each of them highlighting
different combination of driving genes, were recently
described.8–11 None has so far entered routine application.
Recently, we have identified, a 5-genes transcriptomic signa-
ture, which accurately and significantly predicts growth
speed and survival in a prospective series of HCCs at first
presentation.5 This signature (which encounters 5 upregu-
lated genes – angiopoietin-2 (ANGPT2), Delta-like canonical
notch ligand 4 (DLL4), neuropilin and Tolloid-like 2 (NETO2),
endothelial cell-specific molecule 1 (ESM1) and nuclear
receptor subfamily 4 group A member 1 (NR4A1) – all
associated with neo-angiogenesis) was identified through an
extensive microarray study, which also evidenced a large
number of other greatly dysregulated genes. Some of these
associated genes suggested the possibility of a relevant
imbalance of the tissue microenvironment of the HCCs
identified by the transcriptomic signature.
Aim of this study was to identify the circulating and tissue
components of the immune-mediated response of the micro-
environment affecting the aggressiveness and the consequent
clinical outcome in the HCC patients of the original cohort.5
Results
To investigate the effects of the immunological tissue micro-
environment components affecting the HCC clinical outcome,
we performed an extensive study in the prospective cohort
of 132 HCC patients, whose demographic, clinical and bio-
chemical details were previously described5 and are summar-
ized here in Supplementary Table 1. In the blood, we took
into account biochemical parameters, tumoral biomarkers
and cytokines; while in the tissue, we evaluated a high-
throughput transcriptomics corroborated by an immunohisto-
chemical study.
Fast-growing HCCs have significantly higher platelet
(PLT), C-reactive protein (CRP) and alpha-feto protein
(AFP) levels. No significantly different values in biochemical
parameters were found in the fast versus slow-growing HCC
except in platelets count (P= 0.023), CRP (P=0.036) and
AFP levels (P= 0.006). No relationship was found between
higher AFP levels and etiology of liver disease (P=0.843),
presence of portal vein thrombosis either at presentation
(P=0.66) or during short-term follow-up (P=0.811),
Edmondson–Steiner score (P=0.880), tumor-node-meta-
stasis stage (P=0.783). Higher AFP levels were related
with the number of nodules at presentation (P=0.007),
lower HCC doubling time (P= 0.007), higher TGF-β1 levels
(P=0.012). At week 6 after presentation, AFP levels had
significantly (P=0.034) increased in fast but not in slow-
growing HCCs (P=0.726).
In the whole group, apart from TGF-β1, a statistically
significant positive correlation was found between AFP levels
and IGF-2 (P= 0.001) and IL-8 (Po0.0001). In fast-growing
HCCs, a positive correlation was found with adiponectin
(P=0.020), IGF-2 (Po0.0001) and IL-8 (P= 0.008) levels.
In slow-growing HCCs, a negative correlation was found
with angiopoietin-1 (P=0.024) and a positive correlation with
Cyphra 21-1 (P=0.046).
Fast-growing HCCs have significantly higher TGF-β1 and
Cyphra 21-1 levels. In a large panel of 19 cytokines tested,
TGF-β1 and Cyphra 21-1 levels were significantly higher in
fast-growing HCCs (Po0.0001 and P=0.032, respectively),
whereas the circulating levels of all the other cytokines were
not significantly different between fast- and slow-growing
HCCs (Table 1).
Overall, TGF-β1 levels positively correlated with VEGF
(Po0.0001), insulin (P=0.023), Cyphra 21-1 (P=0.001) and
inversely related with Visfatin (P=0.009). Cyphra 21-1 levels
were inversely related with Visfatin only (P=0.001). In fast-
growing HCCs, TGF-β1 positively correlated with Angpt-2 only
(P= 0.042). In slow-growing HCCs, TGF-β1 was positively
related with Cyphra 21-1 (Po0.0001) and VEGF (P=0.002),
and inversely related with Visfatin (P=0.002).
C-type Lectin-like Receptor 2 (CLEC2) is downregulated
and MMPs upregulated in fast-growing HCCs. Further
analysis of hepatic Microarray data5 showed that several
genes were differently dysregulated when the transcriptomic
signature was present. In particular, in fast HCCs, we found a
striking downregulation of CLEC2 and upregulation of several
metalloproteinases (MMPs)(Supplementary Table 2). CLEC2
is a non-classical C-type lectin-like receptor, encoded by the
CLEC1B gene. It is expressed in myeloid cells (including
monocytes, dendritic cells, NK cells and granulocytes), liver
sinusoidal endothelial and Kupffer cells but it has recently
been found also in epithelial cells (and stomach). CLEC2 has
a known exogenous (rhodocytin) and an endogenous ligand
(podoplanin) but other ligands are likely to exist. It has been
shown that CLEC2 is involved in lymphatic/blood vessel
separation, tumor cell-induced platelet aggregation, immune
response and epithelial–mesenchymal transition (EMT).
Hepatic CLEC2 expression was strongly downregulated in
fast compared to slow-growing HCCs (Po0.0001). Other
genes, involved in AKT signaling, were notably dysregulated.
GSK3A (P=0.0069), and eIF4E (P=0.02) were significantly
Table 1 Circulating levels of all the cytokines tested, stratified by slow and fast
HCC (S.D.)
Slow HCCs
(Mean±S.D.)
Fast HCCs
(Mean±S.D.)
P
Angpt1 (ng/ml) 24.389±12.796 25.280±15.482 0.80
Angpt2 (ng/ml) 6.470±4.052 6.471±4.389 0.94
VEGF 288±273 395±311 0.10
Insulin 14.6±7.4 19.5±13.8 0.47
Adiponectin 13.6±9.2 14.1±7.4 0.47
Leptin 11.1±12.4 13.2±9.8 0.75
Visfatina 13.6±8.4 12.1±5.7 0.58
IGF2 8.5±22.0 6.9±17.7 0.20
TGFβ1 (ng/ml) 5.718±3.563 13.111±8.086 0.00
CYFRA21-1 (ng/ml) 6.0±2.9 7.6±3.2 0.03
HGF 1.775±1.046 1.639±755 0.84
IL_1a (pg/ml) 7.1±16.0 8.2±17.3 0.61
IL_1b (pg/ml) 2.1±4.9 4.9±15.66 0.75
IL_6 (pg/ml) 47.1±64.8 84.2±184.9 0.96
IL_8 (pg/ml) 49.6±59.3 79.0±91.0 0.13
IL_10 (pg/ml) 7.1±14.8 3.5±3.2 0.76
TNFα (pg/ml) 4.8±12.0 4.8±9.0 0.21
S.D., standard deviation. Bold values indicate significant values.
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upregulated while PTEN (P= 0.01) and FoxO (P= 0.0019)
were significantly downregulated in fast versus slow HCCs.
In contrast, expression of MMPs was upregulated in fast
respect to slow-growing HCCs, in particular MMP1
(Po0.0001), MMP10 (Po0.0001) and MMP12 (Po0.0001).
A strong inverse relationship was present between hepatic
CLEC2 RNA expression and the different MMP RNAs
(MMP-1: P= 0.002, MMP-10: P= 0.045, MMP-12: P=0.016,
respectively).
Interestingly, CLEC2 downregulation at RNA level was
significantly related with presence, at western blot, of low
molecular weight forms of the protein (∼32 and 25 kD) and
marked decrease or disappearance of the full-size protein
(∼40 kD) (Figures 1a and b) with the presence, in a few cases,
of the 25 kD isoform only. These monomeric low molecular
weight CLEC2 forms, corresponding to forms lacking one
or two of the three glycosylation sites (as indicated by results
of deglycosylation) (Figure 1a), were mostly found in tumor
tissue of poorly differentiated HCCs, especially, but not exclu-
sively, when belonging to the fast phenotype (Figure 1c). In
non-tumor cirrhotic tissue (especially in slow-growing HCCs),
CLEC2 isoforms were normally glycosylated.
At histochemical level, lower CLEC2 expression signifi-
cantly related with poorly differentiated histology (mean optical
density G1-3 versusG4Edmondson score: 0.24± 0.12 versus
0.15±0.07, P=0.033, Mann–Whitney). CLEC2 RNA levels
were also inversely related with circulating TGF-β1 levels, the
highest levels of the latter being found in HCCs in which
CLEC2 was strikingly downregulated (Po0.0001).
CLEC2 downregulation and MMPs upregulation correlate
with clinical outcome. Down- or upregulated genes
affected prognosis and survival. Upregulation of MMP-1,
MMP-10 and MMP-12 was associated with significantly
decreased survival (Supplementary Figure 1). CLEC2 down-
regulation was significantly related with survival, median sur-
vival of HCCs with downregulated CLEC2 being 22 months
versus 54 months (Po0.0001)(Figure 1d). For patients
with downregulated CLEC2, the concomitant presence of
the transcriptomic signature was associated with a further
decrease of median survival. Fast HCCs with CLEC2 lower
than median levels had a median survival of 13 months
versus 27 months (upregulated CLEC2 and aggressive
signature), 44 months (downregulated CLEC2 without
aggressive signature) and 48 months (upregulated CLEC2
and slow HCC) (Po0.0001) (Supplementary Figure 2A). Very
low survival was also observed in patients who displayed
downregulated CLEC2 and poorly differentiated histology.
Patients with downregulated CLEC2 and Edmondson–Stei-
ner (E–S) G4 had a median survival of 7 months versus 26
(CLEC2 downregulated/E–S G1-3), 26 (CLEC2 up/E-D G4)
and 52 months (CLEC2 up/E–S G1-3), respectively
Figure 1 (a) Representative WB analysis of CLEC2 in fast and slow and HCCs. Low molecular weight forms of the protein (∼32 and ∼ 25 kD) were mostly present in fast
HCC, while full-length forms (∼40 kD) were more often present in slow HCCs. These lower bands are consistent with deglicosylated forms. (b) Distribution of different CLEC2
forms in fast and slow HCCs. Columns represent mean of optical density of different isoforms (40, 32 and 25 kD), normalized to β-actin, in slow and fast HCC subgroups (error
bars: S.D.). On the whole, 20 patients (14 with slow tumors and six with fast tumors) were evaluated. (c) Immunohistochemical staining of CLEC2 in the liver shows marked
downregulation of CLEC2 in fast, poorly differentiated HCCs, while slow HCCs displays significantly higher levels of expression. (d) Survival analysis by Kaplan–Meier shows
significantly lower survival in HCC patients with downregulated CLEC2. E–S: Edmondson–Steiner
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(Po0.0001 for all) (Supplementary Figure 2B). Further lower
survival was observed when downregulated CLEC2, E–S G4
and transcriptomic signature were present together (median
survival 6 months) (Po0.0001) (Supplementary Figure 2C).
CLEC2 correlates with low E-cadherin expression in fast-
growing HCCs. Expression of E-cadherin was not signifi-
cantly different in non-tumoral hepatic tissue between
patients with fast and slow HCC (Figure 2a). E-cadherin
positive cells were instead significantly decreased in tumoral
tissue both as intensity and number of positive cells: the loss
of E-cadherin membrane expression was significantly higher
in patients with fast HCCs than in slow HCCs (P=0.014)
(Figures 2a and b). Loss of E-cadherin expression was
significantly related with CLEC-2 downregulation in the tumor,
both at transcriptional (P= 0.005) and post- transcriptional
level (P=0.010).
At RNA level, CDH1 gene was significantly downregulated
in tumoral tissue from fast HCCs versus slow ones (P=0.002).
In non-tumoral tissue the difference did not reach significance
(P=0.096).
MicroRNA in fast-growing HCCs are associated with
TGF-β signaling, angiogenesis and inflammation. To
investigate how gene expression is regulated, we evaluated
a group of 82 microRNA, selected for being associated with
regulation of angiogenesis, cell proliferation, cell signaling,
immune control and autophagy (Supplementary Table 3).
Eighteen microRNAs were differentially expressed in tumor
tissue of fast HCCs in comparison with slow ones (Figure 3).
All these 18 microRNAs but two (146a-5p and 203a) were
upregulated in fast HCCs; in particular, 203a was strongly
downregulated. In slow HCCs, all these microRNAs were
either downregulated or not differentially expressed from
cirrhotic tissue (Figure 3b).
Five microRNA were markedly upregulated in fast HCC
while they were downregulated in slowHCCs: mir-15b-5p, mir-
421, mir-1303, mir-221-3p and mir-486-5p. These microRNAs
are involved in TGF-β/BMP-signaling pathway, angiogenesis,
autophagy and inflammation.
A significant relationship between 16 microRNAs dysregu-
lation and survival was found: downregulation of these
microRNAs in slow HCCs was associated with significantly
better survival, while their upregulation was associated with
significantly worse short- and long-term survival (Supple-
mentary Figure 3). The only exception to that was mir-203a,
whose downregulation in fast HCCs was associated with
significantly worse survival. Lower levels of mir-203a were
also significantly associated with loss of E-cadherin mem-
brane expression in the tumor (P= 0.028).
A signature composed of the five microRNAs most
significantly associated with survival was able to predict
survival both at 12 months and at end of observation
(Figure 4).
PD-1/PD-L1 is more expressed in fast-growing HCCs. To
investigate the immune cells infiltrating tissue microenviron-
ment, we evaluated in paired tumor and non-tumor hepatic
biopsies the expression of PD-1 and PD-L1 and FoxP3.
PD-1 was not only expressed in the lymphocytes infiltrating
the tumor but also on neoplastic hepatocytes (more often with
amembranous expression but, to a lesser extent, cytoplasmic)
(Figures 5a and c). PD-1 positive lymphocytes were almost
absent in the lobular region, being mostly localized in fibrous
septa and in the portal tract. In patients with slow HCC, PD-1
expression in tumor tissue was very weak to negative while
it was strongly positive in most fast HCCs (P= 0.001)
(Figures 5a and b). Expression in NT tissue was much
weaker, although patients with fast HCC displayed relevant
PD-1 expression also in non-tumoral tissue (Figures 5a and b).
PD-L1 was expressed both in tumoral hepatocytes, in
infiltrating lymphocytes cells and in sparse macrophages.
Positive cells were also present in the lobular region. As for
PD-1, much higher PD-L1 expression was found in aggressive
HCCs in comparison with slow ones, in which it was weak to
negative (P=0.013) (Figures 5a and e). PD-1 co-localized
with PD-L1, especially in areas of major lymphocyte infiltration
(Figure 5b) and with FoxP3. A positive correlation was found
between degree of infiltrating lymphocytes and levels of PD-1
and PD-L1 positivity (P= 0.001 and P= 0.029, respectively).
Figure 2 Immunohistochemical analysis of E-cadherin in slow and fast HCCs. (a) E-cadherin membrane localization was preserved in non-tumoral cirrhotic tissue and to a
lesser extent in tumoral tissue in slow HCC. (b) The relative abundance of E-cadherin-positive cells was graded from 0 to 4 by counting with ImageJ software (http://rsbweb.nih.
gov/) at least 100 tumor cells in areas of heterogeneous E-cadherin expression (0= less than 5% of positive cells; 1= 5–25%; 2= 26–50%; 3= 51–75%; and 4= 76–100%).
Forty-three patients were studied (33 with slow HCC, 10 with fast HCC) and the bars represent the number of patients with the different score. Data reported are from tumor tissue.
In fast HCC, E-cadherin membrane expression was reduced in non-tumoral tissue and almost absent in tumoral tissue (P= 0.014)
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Stratifying by biological aggressiveness, the correlation
between lymphocytes infiltration and PD-1 positivity hold
true only for aggressive HCC (fast HCC: P= 0.048; slow:
P= 0.275).
PD-L1 mRNA expression was in agreement with protein
expression: CD274 RNA was significantly more expressed in
high-risk signature HCCs (P= 0.004) in tumoral but not in non-
tumoral tissue (P=0.818). Western blot analysis confirmed
the high level of expression of both PD-1 and PD-L1 in patients
with fast HCC, while in slow HCC they were barely expressed
(Figure 5d).
Discussion
The heterogeneity of HCC represents a major obstacle for
understanding the mechanisms underlying its onset and its
progression.4 Different studies report opposite or discordant
alterations of the same genes or pathways. Possible explana-
tions are the retrospective nature of such studies12 and
surgical resection as a source of tissues specimens, with an
obvious bias of selection among the whole population of
patients. Finally all the previous studies are informative on the
situation at the moment of tissue collection, that is, at
resection, thus representing a snapshot of the disease at
heterogeneous time points of the clinical history. In contrast,
herein we conducted the analysis of the immunological
cellular components of the microenvironment on tissues
obtained by needle biopsy at HCC presentation, in patients
subsequently followed in a longitudinal prospective study. In
this recent study,5 we chose growth speed as indicator
because previous studies from our group13 and others14,15
showed that growth speed strongly relates with progression
and prognosis of HCC. Patients with a tumor doubling time
lower than 53 days carried the neo-angiogenic transcriptomic
signature, which strongly related with rapid progression of
tumor, risk of recurrence after therapy and with extremely low
median survival.5 In the present study, we focused on the
characterization of the microenvironment of HCC in relation
with the presence of the neo-angiogenic transcriptomic
signature. We have found that the biology of fast, aggressive
Figure 3 MicroRNA expression in fast and slow HCCs. (a) All microRNAs but 146a-5p and 203a were significantly overexpressed in fast HCCs (level of significance:
*Po0.01; **Po0.001; ***Po0.0001). Arrows indicated the relationship of each miRNA with survival: white arrows: significantly associated with survival at 12 months gray
arrows: significantly associated with survival at the end of follow-up. (b) MicroRNAs expression in all HCCs versus surrounding non-tumoral cirrhotic tissue, non stratified in fast
and slow HCCs
Figure 4 Survival analysis by Kaplan–Meier: the five microRNA signature tested at presentation was able to predict survival both at 12 months (a) and at the end
of follow-up (b)
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HCCs is profoundly different from that of the slow
subtype. Fast HCCs display a markedly immunosuppressed
microenvironment (as shown by the local upregulation of
both PD-1 and PD-L1) in a background of higher systemic
inflammation, with a distinct switch toward EMT and extreme
poor differentiation at histology. In aggressive HCCs, a set of
MiRNA known to be downregulated or non differentially
expressed from non-tumoral cirrhotic tissue in unstratified
HCCswas found to be paradoxically upregulated in fast HCCs,
contributing to the overall loss of control of immune regulation,
angiogenesis and proliferation.
One of the main findings pointing toward increased local
immunosuppression is the finding of marked PD-1/PD-L1
overexpression. Long-standing inflammation, which is the
common background for both viral and non-viral associated
chronic liver disease, favors cytotoxic T-cell exhaustion and
taking over of T-regs (as shown by high FoxP3 expression).
We do not havemeans of evaluating whether the inflammatory
activity throughout the course of disease had been greater
in aggressive HCCs. However, systemic inflammation, as
evaluated by increased CRP and platelets levels,16,17 was
significantly higher in fast HCCs compared with slow ones.
Only few studies have examined PD-1/PD-L1 in liver cancer.
Recently, a study performed in resected HCC specimens
showed that PD-L1 expression in either neoplastic or
intratumoral inflammatory cells related with macrovascular
and microvascular invasion and poor differentiation.18 PD-1
expression was found only in infiltrating lymphocytes. The
Authors or in alternative, they concluded that these features
related with HCC characterized by higher AFP levels and
lymphoepithelioma-like histological subtype. These results
are in agreement with our findings. In our prospective series of
HCC studied at presentation, we demonstrated that the most
aggressive HCCs (defined by the transcriptomic signature)
have relevant expression of PD-1/PD-L1 while slow HCCs do
not. As not more than 20% of HCCs carry the transcriptomic
signature, this means that PD1/PD-L1 would be definitely
positive in about 1/5 of cases only. This has implications for
Figure 5 (a) Immunohistochemical demonstration of PD-1 and PD-L1 in slow and fast HCCs. Fast HCCs display strong positivity, localized in the lymphocytic infiltrate. (b)
PD-1- and PD-L1-positive cells co-localize in the areas of stronger lymphocytic infiltrate. (c) In fast HCC, both PD-1 and PD-L1 can be demonstrated in hepatocytes. (d) Western
blot analysis confirms the higher level of positivity of fast HCCs in comparison with slow HCCs, which are weakly positive or negative in the tumor. (e) Semi-quantification of PD-1
and PD-L1 in tumor tissue of fast and slow HCCs. Columns represent mean of optical density, normalized to β-actin, of 20 patients (14 with slow tumors and six with fast tumors)
(error bars: S.D.). PD-1 and PD-L1 levels were significantly different between slow and fast HCCs (P= 0.0005 and P= 0.0002, respectively)
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therapeutic strategies with PD-1/PD-L1 inhibitors: although
there are indications that check point inhibitors have some
activity independently from PD-1/PD-L1 status, strongly
positive cases are reported to have higher response.19 We
also found intense PD-1 expression not only in infiltrating
lymphocytes but also on tumoral hepatocytes. This is a novel
finding in HCC. There are reports, however, of the presence of
PD-1 on tumor cells in other tumors with a relevant
inflammatory background like melanoma.20 Inflammation
has been shown to be a key driver also for the induction of
PD-L1.21 What is clear from our data is the strict relationship
between entity of lymphocytic infiltrate, PD1/PD-L1 positivity
and aggressive HCC phenotype. This has clear therapeutic
implications: these patients have an extremely severe prog-
nosis, especially if they have also poorly differentiated
histology, with a median survival as low as 6 months.
Checkpoints inhibitors could represent a substantial chance
of cure for these patients.
Another striking finding in this cohort of HCCs was the
marked downregulation of CLEC2. CLEC2 is a non-classical
C-type lectin-like receptor, which is expressed on platelet and
hematopoietic cells.22,23 CLEC2 localization in epithelial cells
has been rarely reported.24 Interestingly, the recent study by
Wang et al.25 showed that CLEC2 is present in normal gastric
mucosa but is downregulated in gastric tumors. CLEC2
downregulation relates with depth of tumor invasion, metas-
tasis to lymph node, and 5-year survival of patients. They
concluded that CLEC2 inhibits Akt signaling by blocking
expression of phosphoinositide 3-Kinase and may act as a
suppressor of tumor transformation and metastasis in gastric
cancer. Our data in HCC are consistent with those by Wang
et al.25 in gastric cancer. We showed that CLEC2 is
abundantly expressed in non-tumoral liver tissue in fully
glycosylated form, while its expression is markedly decreased
or absent in HCC, and present in bi- or mono-glycosylated
form. Furthermore, CLEC-2 was downregulated in liver cancer
at both transcriptional and post-translational levels; this
significantly related with upregulation of genes related with
Akt signaling like GSK3 and eIF4E, with PTEN downregula-
tion, with poorly differentiated histology (i.e., G4 in the
Edmondson–Steiner classification), aggressive HCC pheno-
type bearing the transcriptomic signature and evidence of
EMT. These patients had a median survival of 6 months.
The pattern of microRNA expression was also very
distinctive. Only 17 out of 82 microRNAs tested were
differentially expressed in fast in comparison with slow HCCs.
All microRNAs identified but two (mir-146a-5p and miR-203a)
were overexpressed in aggressive HCCs and downregulated
in slow HCCs. The top five overexpressed microRNAs (mir-
15b-5p, mir-421, mir-1303, mir-221-3p and mir-486-5p) were
very informative of the activated pathways in these HCCs. Two
of them (mir-15b-5p and mir-421) are involved in TGFβ1
pathway and in inflammatory signaling;26,27 mir-15b-5p is also
involved in G1-S transition.28 Mir-1303 modulates prolifera-
tion, migration and cell invasion and differentially controls
Glypican-3 expression in HCC cells.29 Mir-221-3p is involved
in cell cycle progression and has a oncogenic role in gastric
carcinoma.30,31 Mir-486-5p has a role in angiogenesis,
lymphangiogenesis, and cell proliferation.32,33 For some of
these microRNAs, discordant indications on their role in
HCC exist. Increased mir-15b-5p was negatively correlated
with HCC recurrence.34 Yang et al.35 suggested that mir-15b-
5p acted as a tumor suppressor gene in HCC inducing
endoplasmic reticulum stress, apoptosis, and growth inhibition
by targeting and suppressing Rab1A. However, Liu et al.27
found elevated mir-15b-5p in HCC tissue and in the serum,
which decreased after curative resection, thus suggesting a
causal role for mir-15b-5p in HCC progression. Mir-486-5p
was previously reported as downregulated in several cancers,
among which HCC; the low mir-486-5p expression in HCC
tissue was associated with high recurrence rate and poor
disease-free survival after tumor resection.36 Experimental
overexpression of mir-486-5p markedly suppressed HCC cell
proliferation and inhibited HCC growth in vivo. These findings
are in contrast with our data. We found a significantly worse
survival in patients, also carrier of the transcriptomic signature,
with upregulated mir-15b-5p or mir-486-5p. A partial explana-
tion can be the different composition of the patients’ cohorts.
Studies with discordant results34–36 investigated HCC sam-
ples derived from resection, representative of the small
percentage of slow-growing HCCs liable to this type of therapy
but having a different biological behavior than the fast ones.
Most important, however, is the fact that fast HCCs are similar
to other aggressive inflammatory cancers, which show
microRNA dysregulation concordant with our results. In these
cancers, like sebaceous carcinoma37 or glioma38 a strong
relationship between overexpressed mir-486-5p and worse
outcome was found. In this context, mir-486-5p represses
several regulators of nuclear factor (NF)-KB, thus favoring
persisting inflammation and further cytotoxic T-cell exhaustion.
To further underline the relevance of the inflammatory back-
ground in determining the pattern of microRNA dysregulation,
mir-486-5p together with mir-421, mir-1303, mir-221-3p (all
notably upregulated in fast HCCs) are comprised in a 5-gene
microRNA signature, predictive of breast tumor aggressive-
ness, recently described in inflammatory breast cancer
(IBC).39 This signature, which accurately predicts IBC
phenotype with an overall accuracy of 89%, identifies a type
of breast cancer that shares many features with the fast HCCs
of our cohort, that is, intense angiogenesis, high proliferation
and metastatic ability. IBCs are also characterized by
transcriptomic signatures strongly upregulated for NF-KB-
dependent genes and downregulated for estrogen-dependent
genes, a feature also present in our fast HCCs (data not
shown). On the whole, these characteristics underline the
extreme importance of the inflammatory background of liver
disease, with many of the microRNAs involved with inflamma-
tion having a role also in angiogenesis. Most interestingly, the
only significantly downregulated microRNA in fast HCCs was
mir-203a, which has been reported to act as an anti-oncogene
to suppress HCC tumorigenesis and to be a marker of
poor prognosis of HCC when downregulated.40,41 Loss of
miR-203a results in activation of EMT in normal hepatocytes
and HCC tumor cells and is associated with prominent
downregulation of E-cadherin expression, as we showed in
fast HCCs.40
In conclusion, we have characterized the circulating and
tissue components of the microenvironment of fast HCCs.
Apart from redundant neo-angiogenesis,5 fast HCCs bear
very unique features of distinctively immunosuppressed
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microenvironment, prominent EMT, and noticeable activation
of TGFβ1 signaling in a general background of long-standing
and permanent inflammatory state (Figure 6). This suggests
that every effort should be made throughout the long
natural history of patients with liver disease to switch off the
inflammatory process, whatever the cause, as early as
possible.
Materials and Methods
The patients investigated in this study were those previously reported in a prospective
genome-wide transcriptomic study, in which a 5-gene signature was identified which
accurately defined HCC growth rate and patients’ survival characteristics.5 Growth
rate was studied by a specifically set up imaging protocol and internally validated in an
independent prospective cohort.5 Demographic, clinical and biochemical details of
the training and validation cohorts are reported in Supplementary Table 1. Enrollment
in the study started in 2008; median follow-up was 36 months.
Determination of serum cytokines. Interleukin (IL)-1 alpha, IL-1beta,,
IL-10, tumor necrosis factor (TNF)-alpha (Aushon Biosystems, Billerica, MA, USA),
Adiponectin (DRG International, Springfield, NJ, USA; NJ, USA), Visfatin (Phoenix
Pharmaceutical, Inc., Burlingame, CA, USA)., Insulin-like growth factor (IGF)-2
(Boster Biological Technology, Pleasanton, CA, USA), and Hepatocyte growth factor
(HGF) (Aushon Biosystems, Inc., Billerica, MA, USA), were measured in duplicate,
according to the manufacturer’s instructions. Serum CYFRA21-1 was tested with the
human cytokeratin fragment antigen 21-1 (CYFRA21-1) ELISA kit (Cusabio Biotech
Co., Ltd, Wuhan, P.R. China) according to the manufacturer’s instructions. Serum
IL-6, TNF-alpha, IL-8, VEGF, and TGF-β1 levels were determined with the
quantikine/high-sensitivity enzyme-linked immunosorbent assay kit (R&D Systems,
Minneapolis, MN, USA), according to the manufacturer’s instructions.
Absorbances were measured at 450 and 490 nm with an automatic microplate
reader (Multiskan EX; Thermo Fisher Scientific, Inc, Waltham, MA, USA), with
background subtraction at 570 and 650 nm, respectively.
Immunohistochemistry. Immunostaining was performed on 5-μm sections
of formalin-fixed and paraffin-embedded tissues of the original biopsies obtained at
presentation, also evaluated for transcriptomic and microRNA analysis. Sections
were incubated for 30 min at 98 °C with 10 mM citrate buffer pH 6.0 or EDTA buffer
pH 8, depending on antibody used, for antigen retrieval, treated with 3% hydrogen
peroxide for 10 min and blocked using a blocking solution reagent for 1 h at room
temperature. Sections were then incubated with either (a) rabbit monoclonal
antibody for PD-L1 (E1L3N) (Cell Signaling Technology, Inc., Danvers, MA, USA) at
working dilution of 1:80/rabbit monoclonal antibody for PD-1 (D4W2J) diluted 1:100
at 4 °C overnight; (b) mouse monoclonal antibody for FoxP3 (1:50, clone 236A/E7;
eBioscience, San Diego, CA, USA); (c) mouse polyclonal antibody for C-type lectin-
like receptor 2 (CLEC-2 /CLEC1B) (working dilution 1:80) (Ventana Medical
Systems, Tucson, AZ, USA); or (d) with pre-diluted (ready-to-use) mouse
monoclonal antibody against E-cadherin (Ventana Medical Systems, Tucson, AZ,
USA) at 37 °C for 24–38 min. Sections were then incubated with detection kit
reagents (Ultra view universal HRP multimer and Diaminobenzidine (DAB)
Chromogen, Ventana Medical Systems, Inc., Tucson, AZ, USA) following the
manufacturer’s instructions. The sections were then counterstained with hematox-
ylin,dehydrated and permanently mounted for microscopic examination. Images of
stained liver tissue were processed with ImageJ software (http://rsbweb.nih.gov/) to
obtain the medium intensity value of DAB signal. Three fields were chosen at
random under 200-fold magnification; the number of stained cells for each intensity
level was counted. Cases were scored as weak, intermediate, and strong brown
staining. The expression score was calculated according to the formula: = 0 ×% of
non-stained tumor cells + 1 ×% of weakly stained tumor cells + 2 ×% of moderately
stained tumor cells + 3 ×% of strongly stained tumor cells. An expression score
between 0 and 30 was obtained where 30 was equal to 100% of tumor cells strongly
stained.42,43 Two pathologists independently performed the semi-quantitative
estimation of immunoreactive cells, based on staining intensity and relative cellular
abundance.
MicroRNA
RNA Extraction and real-time PCR analysis: The total RNA used for this
study was a portion of the RNA used for the published transcriptomic analysis.5
Mature microRNAs extracted from liver tumor and non-tumor tissue were reverse
transcribed and amplified using the miRCURY LNATM Universal RT microRNA PCR
system (EXIQON, Inc., Woburn, MA, USA). qRT-PCR was performed in a LightCycler
480 instrument (Roche, Mannheim, Germany) using miRCURY LNATM SYBR Green
master mix (EXIQON) and Custom microRNA LNATMPCR primer set (EXIQON) in
10 μl reaction, at volume of 10 ng complementary DNA (cDNA)/RNA concentration.
The reactions were incubated in a 96-well plate at 95 °C for 10 min, 45 cycles of 95 °
C for 10 s, 60 °C for 1 min. Each sample was analyzed in duplicate. The level of
microRNA expression was measured using Ct (threshold cycle). The 2-ΔΔCt
method for relative quantification of gene expression was used to determine miRNA
expression levels. The ΔCt was calculated by subtracting the Ct of U6 and RNAU5G
from the Ct of the microRNA of interest. Using this method, we obtained the fold
changes of gene expression normalized to two internal control genes and relative to
the corresponding cirrhotic non-tumor liver tissue.
Western blot analysis. Liver tissue was completely dissociated with
Gentlemax Dissociator (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany),
according to the manufacturers' instructions, in ice-cold RIPA buffer, supplemented
with protease inhibitors (Complete; Roche Applied Science, Mannheim, Germany)
and phosphatase inhibitors (PhosSTOP; Roche Applied Science). Protein
concentration was determined by BCA method (Quantum micro protein kit;
Euroclone Spa, Pero, MI, Italy). 20 μg of protein extracts were subjected to reducing
10% sodium-dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a
PVDF membrane (GE Healthcare, Amersham, UK), which was probed with CLEC2/
CLEC1b-specific Antibody (MAB1718; R&D System, Minneapolis, MN, USA), PD-1
(D4W2J) XP Rabbit mAb (#86163, Cell Signaling Technology, Inc., Danvers, MA,
USA) and PD-L1 (E1L3N) XP Rabbit mAb (#13684, Cell Signaling Technology, Inc.)
overnight at 4 °C, after being blocked with a 5% solution of nonfat dry milk dissolved
in blotting buffer (25 mM Tris, 0.15 M NaCl, 0.1% Tween 20, pH 7.4) or T.
Membranes were subsequently washed and exposed for 1 h at room temperature to
a secondary mouse IgG horseradish peroxidase-conjugated antibody (HAF018;
R&D System) and to a secondary rabbit IgG horseradish peroxidase-conjugated
antibody (SC2004; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) and detected
by chemiluminescence (LiteAblot Plus; Euroclone Spa, Pero, MI, Italy) followed by
autoradiography and densitometry analysis by Quantity One 1-D Analysis Software
(BioRad, Hercules, CA, USA).
Figure 6 A graphic abstract showing the major findings of this study. The
distinctive features of fast and slow HCCs are depicted
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Enzymatic deglycosylation: 50 μg of total protein extract was denatured in
0.1% SDS, 0.1 M 2-Mercaptoethanol buffer, for 5 min at 95 °C. The samples were
incubated for 4 h at 37 °C with N-glycosidase F (Roche Applied Science) in
deglycosylation buffer (400 mM Sodium phosphate mono/dibasic, pH 7.4) with the
addition of protease inhibitor (Complete; Roche Applied Science) and 0.8% v/v
Nonidet P40 (Roche applied Science) as described by Viapiano Lab (Boston, MA,
USA), 2007. Bovine fetuin (Sigma Aldrich, Inc., St. Louis, MO, USA) was used as a
control glycoprotein. Enzyme reactions were subsequently analyzed by SDS-PAGE
and western Blot analysis.
Statistical analysis. Dichotomous and continuous variables were compared
using Fisher’s exact test and the nonparametric Mann–Whitney U-test, respectively.
The Kaplan–Meier method was used to estimate the cumulative probability of
overall survival. Patients were censored at the time of LT, death or the last available
follow-up. Differences in observed probability were assessed using the log-rank test.
The PASW Statistics 20 program (IBM Corp., Armonk, NY, USA) was used for
statistical analyses.
All the authors had access to the study data and reviewed and approved the final
manuscript.
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